Petri

Molecule GmbH is a company that has developed a virtual accelerator platform aimed at facilitating the translation of scientific discoveries into new therapeutics. Founded in 2018 and headquartered in Neuhausen am Rheinfall, Switzerland, with an additional office in Berlin, Germany, Molecule connects scientists with the necessary funding for therapeutic development. This platform also links private investors directly with scientists, promoting the advancement of various treatments for patients. By streamlining the innovation process within the pharmaceutical industry, Molecule seeks to enhance the efficiency of bringing novel therapeutics to market.

Compound Foods creates coffee without coffee beans

Compound Foods creates coffee without coffee beans

New Equilibrium Biosciences focuses on the research and development of therapeutic drugs aimed at treating cancer, neurodegenerative diseases, and other medical conditions. The company specializes in targeting intrinsically disordered proteins (IDPs), which play a significant role in various disorders. By integrating artificial intelligence with quantum chemistry, New Equilibrium leverages biophysical experiments to explore opportunities for structure-based drug design. This approach includes the creation of compound libraries specifically for IDPs, allowing for the identification of potential drug candidates that can interact with transient binding pockets on these proteins. Through its innovative platform, New Equilibrium aims to enhance drug discovery processes and improve treatment options within the healthcare sector.

Yard Stick PBC is an in-situ soil carbon & bulk density measurement technology.

Medsix is a company focused on improving the management of wound drains for patients undergoing complex surgeries or those with slow healing processes. Traditional methods of monitoring drain output rely on manual assessments by nurses or patients, which can lead to inaccuracies, resulting in prolonged drain use and missed early signs of complications such as infections or blockages. To address these issues, Medsix is developing a disposable sensor that can be attached to any wound drain, incorporating predictive analytics to automate monitoring. This innovation aims to enhance patient outcomes by facilitating earlier detection of complications and enabling timely removal of drains, thereby reducing recovery times. Additionally, it seeks to improve clinical workflows for healthcare providers and create standardized practices for wound drain management. For payers, the system is designed to decrease hospital stays and readmission rates, ultimately increasing reimbursement efficiencies.

GALY Inc. is a biotechnology company that specializes in producing lab-grown cotton through innovative biomaterial technology. Founded in 2019 and based in the United States, the company uses synthetic biology to cultivate cotton cells in a laboratory setting, offering a sustainable alternative to traditional cotton production. GALY's cellular cotton yarns are designed to meet the needs of the textile industry, providing high-quality raw materials that are more cost-effective and environmentally friendly than conventional cotton. By utilizing proprietary methods, GALY aims to reduce the ecological impact associated with cotton farming, thereby supporting clothing brands and textile manufacturers in their pursuit of sustainable practices.

Matterworks accelerates the discovery and engineering through faster and more comprehensive metabolomic screening.

New Equilibrium Biosciences focuses on the research and development of therapeutic drugs aimed at treating cancer, neurodegenerative diseases, and other medical conditions. The company specializes in targeting intrinsically disordered proteins (IDPs), which play a significant role in various disorders. By integrating artificial intelligence with quantum chemistry, New Equilibrium leverages biophysical experiments to explore opportunities for structure-based drug design. This approach includes the creation of compound libraries specifically for IDPs, allowing for the identification of potential drug candidates that can interact with transient binding pockets on these proteins. Through its innovative platform, New Equilibrium aims to enhance drug discovery processes and improve treatment options within the healthcare sector.